194 related articles for article (PubMed ID: 33175088)
1. Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial.
Asakura M; Ito S; Yamada T; Saito Y; Kimura K; Yamashina A; Hirayama A; Kobayashi Y; Hanatani A; Tsujimoto M; Yasuda S; Abe Y; Higashino Y; Tamaki Y; Sugino H; Niinuma H; Okuhara Y; Koitabashi T; Momomura SI; Asai K; Nomura A; Kawai H; Satoh Y; Yoshikawa T; Hirata KI; Yokoi Y; Tanaka J; Shibata Y; Maejima Y; Tamaki S; Kawata H; Iwahashi N; Kobayashi M; Higuchi Y; Kada A; Yamamoto H; Kitakaze M
Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):108-117. PubMed ID: 33175088
[TBL] [Abstract][Full Text] [Related]
2. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
4. Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).
Asakura M; Yamamoto H; Asai K; Hanatani A; Hirata K; Hirayakma A; Kimura K; Kobayashi Y; Momomura S; Nakagawa Y; Nishi Y; Saito Y; Satoh Y; Yamada T; Yamashina A; Yasuda S; Yoshikawa T; Kada A; Uesaka H; Kitakaze M;
Cardiovasc Drugs Ther; 2015 Apr; 29(2):179-85. PubMed ID: 25566817
[TBL] [Abstract][Full Text] [Related]
5. Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
Larsson JE; Denholt CS; Thune JJ; Raja AA; Fosbøl E; Schou M; Køber L; Nielsen OW; Gustafsson F; Kristensen SL
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):546-552. PubMed ID: 37355774
[TBL] [Abstract][Full Text] [Related]
6. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF).
Tsutsui H; Ito H; Kitakaze M; Komuro I; Murohara T; Izumi T; Sunagawa K; Yasumura Y; Yano M; Yamamoto K; Yoshikawa T; Tsutamoto T; Zhang J; Okayama A; Ichikawa Y; Kanmuri K; Matsuzaki M;
Circ J; 2017 Dec; 82(1):148-158. PubMed ID: 28824029
[TBL] [Abstract][Full Text] [Related]
7. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Montalescot G; Pitt B; Lopez de Sa E; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Vincent J; Zannad F; ;
Eur Heart J; 2014 Sep; 35(34):2295-302. PubMed ID: 24780614
[TBL] [Abstract][Full Text] [Related]
8. Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
Monzo L; Girerd N; Duarte K; Ferreira JP; McMurray JJV; van Veldhuisen DJ; Swedberg K; Pocock SJ; Pitt B; Zannad F
Eur J Heart Fail; 2023 Aug; 25(8):1444-1449. PubMed ID: 37370197
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone in patients with systolic heart failure and mild symptoms.
Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B;
N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Filippatos G; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Kim SY; Nowack C; Palombo G; Kolkhof P; Kimmeskamp-Kirschbaum N; Pieper A; Pitt B
Eur Heart J; 2016 Jul; 37(27):2105-14. PubMed ID: 27130705
[TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Higuchi H; Sai S; Nakatsukasa T; Sugano A; Baba M; Obara K; Aonuma K
Heart Vessels; 2019 Feb; 34(2):279-289. PubMed ID: 30203391
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
16. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
17. Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
Sudano I; Naegele M; Roas S; Périat D; Frank M; Kouroedov A; Noll G; Lüscher TF; Enseleit F; Ruschitzka F; Flammer AJ
Clin Cardiol; 2016 May; 39(5):285-90. PubMed ID: 26991772
[TBL] [Abstract][Full Text] [Related]
18. Effect of eplerenone on clinical stability of Japanese patients with acute heart failure.
Kobayashi M; Ferreira JP; Matsue Y; Chikamori T; Ito S; Asakura M; Yamashina A; Kitakaze M
Int J Cardiol; 2023 Mar; 374():73-78. PubMed ID: 36586516
[TBL] [Abstract][Full Text] [Related]
19. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Olivier A; Pitt B; Girerd N; Lamiral Z; Machu JL; McMurray JJV; Swedberg K; van Veldhuisen DJ; Collier TJ; Pocock SJ; Rossignol P; Zannad F; Pizard A
Eur J Heart Fail; 2017 Sep; 19(9):1186-1197. PubMed ID: 28303624
[TBL] [Abstract][Full Text] [Related]
20. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
